Foreign-Trade Zone 22-Chicago, IL, Notification of Proposed Production Activity, Abbott Laboratories, Inc., AbbVie, Inc. (Pharmaceutical Production), North Chicago, IL, Area, 75610 [2012-30848]
Download as PDF
<![CDATA[
75610
Federal Register / Vol. 77, No. 246 / Friday, December 21, 2012 / Notices
Now, therefore, the Board hereby
grants to the Grantee the privilege of
establishing a foreign-trade zone,
designated on the records of the Board
as Foreign-Trade Zone No. 284, as
described in the application, and subject
to the FTZ Act and the Board’s
regulations, including Section 400.13, to
the Board’s standard 2,000-acre
activation limit for the overall generalpurpose zone, and to an ASF sunset
provision for magnet sites that would
terminate authority for Site 1 if not
activated within five years from the date
of approval.
Signed at Washington, DC, this 4th day of
December 2012.
Rebecca Blank,
Acting Secretary of Commerce, Chairman and
Executive Officer, Foreign-Trade Zones
Board.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2012–30846 Filed 12–20–12; 8:45 am]
BILLING CODE 3510–DS–P
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B–91–2012]
mstockstill on DSK4VPTVN1PROD with
Foreign-Trade Zone 22—Chicago, IL,
Notification of Proposed Production
Activity, Abbott Laboratories, Inc.,
AbbVie, Inc. (Pharmaceutical
Production), North Chicago, IL, Area
Abbott Laboratories, Inc. (Abbott) and
AbbVie, Inc. (AbbVie) submitted a
notification for expanded production
authority within Subzones 22F and 22S,
at sites located in the North Chicago and
Lake County, Illinois, area. The facilities
are used for the production of a wide
variety of pharmaceutical and
diagnostic products, medical devices
and equipment. The notification
conforming to the requirements of the
regulations of the Board (15 CFR 400.22)
was received on December 14, 2012.
Subzone 22F was approved by the
Board in 1992 (Board Order 611, 12/14/
1991, 57 FR 61045, 12/14/1992) and
authority was later expanded in 1999
and 2009 (Board Order 1051, 8/30/1999,
64 FR 48578, 9/7/1999 and Board Order
1654, 12/18/2009, 75 FR 340–341, 1/5/
2010). A minor boundary modification
under 15 CFR 400.38 of the Board’s
regulations was approved, effective
August 1, 2012, transferring two sites
from SZ 22F at the Abbott facilities to
AbbVie, now designated as Subzone 22S
(S–66–2012).
Abbott and Abbvie are now requesting
authority to use production inputs
sourced from abroad that include:
VerDate Mar<15>2010
18:28 Dec 20, 2012
Jkt 229001
Peptones and their derivatives; other
protein substances and their derivatives;
and heterocyclic compounds, aromatic
compounds, sulfanomides, and catalysts
used in discovery, research and
development (duty rates range from
3.7% to 6.5%).
Production under FTZ procedures
could exempt Abbott/AbbVie from
customs duty payments on the foreign
status inputs used in export production
for the additional activity proposed. On
its domestic sales, for the foreign status
inputs noted above, Abbott/AbbVie
would be able to choose the duty rates
during customs entry procedures that
apply to the following additional
pharmaceutical products that include
active ingredients, placebo, and protein
used in research and development:
Placebo products intended for clinical
trials; radioactive elements and isotopes
and compounds other than those of
subheadings 2844.10, 2844.20, and
2844.30; alloys; dispersions (including
cermets); ceramic products and
mixtures containing these elements;
isotopes or compounds; radioactive
residues; elements, isotopes and
compounds with cobalt-60 radioactivity
only; and other elements, isotopes and
compounds: Americium-241,
californium-252, curium-244, cesium137, gadolinium-153, iridium-192,
promethium-147, radium-266,
selenium-75, or ytterbium-169; peptones
and their derivatives; and other protein
substances and their derivatives (duty
free–6.4%). Customs duties also could
possibly be deferred or reduced on
foreign status production equipment.
Public comment is invited from
interested parties. Submissions shall be
addressed to the Board’s Executive
Secretary at the address below. The
closing period for their receipt is
January 30, 2013.
A copy of the notification will be
available for public inspection at the
Office of the Executive Secretary,
Foreign-Trade Zones Board, Room
21013, U.S. Department of Commerce,
1401 Constitution Avenue NW.,
Washington, DC 20230–0002, and in the
‘‘Reading Room’’ section of the Board’s
Web site, which is accessible via
www.trade.gov/ftz. For further
information, contact Diane Finver at
Diane.Finver@trade.gov (202) 482–1367.
Dated: December 14, 2012.
Executive Secretary.
[FR Doc. 2012–30848 Filed 12–20–12; 8:45 am]
BILLING CODE P
PO 00000
Frm 00005
Fmt 4703
Sfmt 4703
DEPARTMENT OF COMMERCE
National Institute of Standards and
Technology
Advisory Committee on Earthquake
Hazards Reduction Meeting
National Institute of Standards
and Technology, Department of
Commerce.
ACTION: Notice of open meeting.
AGENCY:
The Advisory Committee on
Earthquake Hazards Reduction (ACEHR
or Committee), will hold an open
meeting via teleconference on Thursday,
January 10, 2013 from 1:00 p.m. to 3:00
p.m. Eastern Time. The primary purpose
of this meeting is to review the
Committee’s draft letter report to the
NIST Director. Any draft meeting
materials will be posted prior to the
meeting on the National Earthquake
Hazards Reduction Program (NEHRP)
Web site at https://nehrp.gov/. Interested
members of the public will be able to
participate in the meeting from remote
locations by calling into a central phone
number.
DATES: The ACEHR will hold a meeting
via teleconference on Thursday, January
10, 2013, from 1:00 p.m. until 3:00 p.m.
Eastern Time. The meeting will be open
to the public.
ADDRESSES: Questions regarding the
meeting should be sent to NEHRP
Director, National Institute of Standards
and Technology, 100 Bureau Drive, Mail
Stop 8604, Gaithersburg, Maryland
20899–8604. For instructions on how to
participate in the meeting, please see
the SUPPLEMENTARY INFORMATION section
of this notice.
FOR FURTHER INFORMATION CONTACT: Dr.
Jack Hayes, National Earthquake
Hazards Reduction Program Director,
National Institute of Standards and
Technology, 100 Bureau Drive, Mail
Stop 8604, Gaithersburg, Maryland
20899–8604. Dr. Hayes’ email address is
jack.hayes@nist.gov and his phone
number is (301) 975–5640.
SUPPLEMENTARY INFORMATION: The
Committee was established in
accordance with the requirements of
Section 103 of the NEHRP
Reauthorization Act of 2004 (Pub. L.
108–360). The Committee is composed
of 14 members appointed by the
Director of NIST, who were selected for
their technical expertise and experience,
established records of distinguished
professional service, and their
knowledge of issues affecting the
National Earthquake Hazards Reduction
Program. In addition, the Chairperson of
the U.S. Geological Survey (USGS)
Scientific Earthquake Studies Advisory
SUMMARY:
E:\FR\FM\21DEN1.SGM
21DEN1
]]>Agencies
[Federal Register Volume 77, Number 246 (Friday, December 21, 2012)]
[Notices]
[Page 75610]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-30848]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-91-2012]
Foreign-Trade Zone 22--Chicago, IL, Notification of Proposed
Production Activity, Abbott Laboratories, Inc., AbbVie, Inc.
(Pharmaceutical Production), North Chicago, IL, Area
Abbott Laboratories, Inc. (Abbott) and AbbVie, Inc. (AbbVie)
submitted a notification for expanded production authority within
Subzones 22F and 22S, at sites located in the North Chicago and Lake
County, Illinois, area. The facilities are used for the production of a
wide variety of pharmaceutical and diagnostic products, medical devices
and equipment. The notification conforming to the requirements of the
regulations of the Board (15 CFR 400.22) was received on December 14,
2012.
Subzone 22F was approved by the Board in 1992 (Board Order 611, 12/
14/1991, 57 FR 61045, 12/14/1992) and authority was later expanded in
1999 and 2009 (Board Order 1051, 8/30/1999, 64 FR 48578, 9/7/1999 and
Board Order 1654, 12/18/2009, 75 FR 340-341, 1/5/2010). A minor
boundary modification under 15 CFR 400.38 of the Board's regulations
was approved, effective August 1, 2012, transferring two sites from SZ
22F at the Abbott facilities to AbbVie, now designated as Subzone 22S
(S-66-2012).
Abbott and Abbvie are now requesting authority to use production
inputs sourced from abroad that include: Peptones and their
derivatives; other protein substances and their derivatives; and
heterocyclic compounds, aromatic compounds, sulfanomides, and catalysts
used in discovery, research and development (duty rates range from 3.7%
to 6.5%).
Production under FTZ procedures could exempt Abbott/AbbVie from
customs duty payments on the foreign status inputs used in export
production for the additional activity proposed. On its domestic sales,
for the foreign status inputs noted above, Abbott/AbbVie would be able
to choose the duty rates during customs entry procedures that apply to
the following additional pharmaceutical products that include active
ingredients, placebo, and protein used in research and development:
Placebo products intended for clinical trials; radioactive elements and
isotopes and compounds other than those of subheadings 2844.10,
2844.20, and 2844.30; alloys; dispersions (including cermets); ceramic
products and mixtures containing these elements; isotopes or compounds;
radioactive residues; elements, isotopes and compounds with cobalt-60
radioactivity only; and other elements, isotopes and compounds:
Americium-241, californium-252, curium-244, cesium-137, gadolinium-153,
iridium-192, promethium-147, radium-266, selenium-75, or ytterbium-169;
peptones and their derivatives; and other protein substances and their
derivatives (duty free-6.4%). Customs duties also could possibly be
deferred or reduced on foreign status production equipment.
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary at the address
below. The closing period for their receipt is January 30, 2013.
A copy of the notification will be available for public inspection
at the Office of the Executive Secretary, Foreign-Trade Zones Board,
Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW.,
Washington, DC 20230-0002, and in the ``Reading Room'' section of the
Board's Web site, which is accessible via www.trade.gov/ftz. For
further information, contact Diane Finver at Diane.Finver@trade.gov
(202) 482-1367.
Dated: December 14, 2012.
Executive Secretary.
[FR Doc. 2012-30848 Filed 12-20-12; 8:45 am]
BILLING CODE P
